Gilead Sciences, Inc.

Gilead Pharmasset LLC

Scott D Schroeder

John O Link

Winston C Tse

Jennifer R Zhang

James G Taylor

Jeromy J Cottell

Michael Graupe

Eda Y Canales

Qi Liu

Michael L Mitchell

William John Watkins

Scott E Lazerwith

Elizabeth M Bacon

Randall Halcomb

Thorsten A Kirschberg

Darryl Kato

Hongyan Guo

Chienhung Chou

Hyung-Jung Pyun

Nathan E Wright

Jiayao Li

Randall W Vivian

Richard L Mackman

Sheila M Zipfel

Gediminas J Brizgys

Carina E Cannizzaro

Choung U Kim

Manoj C Desai

Aesop Cho

Lianhong Xu

Jay P Parrish

Hongtao Liu

Jianyu Sun

Gary Bruce Phillips

Musong Kim

Christopher T Clark

Zheng-Yu Yang

Lan Jiang

Hong Yang

Dimitrios Stefanidis

Devan Naduthambi

Elbert Chin

Kevin S Currie

Chandrasekar Venkataramani

Dustin S Siegel

Barton W Phillips

Hon Chung Hui

Michael O'Neil Hanrahan Clarke

Haolun Jin

Samuel E Metobo

Ryan McFadden

Michael R Mish

Julian Andrew Codelli

Chien-Hung Chou

Qiaoyin Wu

Roland D Saito

Nathan D Shapiro

Steven S Bondy

Yunfeng Eric Hu

Evan S Krygowski

James D Trenkle

Joseph H Saugier

Neil H Squires

Kirk L Stevens

Stephen E Ammann

Gayatri Balan

Hang Chu

Weng K Chang

Henok H Kinfe

Ana Zurisadai Gonzalez Buenrostro

Gregory F Chin

Xiaochun Han

Chien-hung Chou

Chao-I Hung

Devleena M Shivakumar

Daniel G Shore

Christopher J Swank

Joshua J Van Veldhuizen

Rhiannon Thomas-Tran

Yasamin Moazami

Gregg M Schwarzwalder

Jason K Perry

Suzanne M Szewczyk

James S Cassidy

Kavoos Kolahdouzan

Hai Yang

Mark J Bartlett

David W Lin

Evangelos Aktoudianakis

Julie Farand

Michael O Clarke

Jennifer Leigh Cosman

Bindu Goyal

Yafan Lu

Charles William Rowe

Doris T Tang

Tezcan Guney

James B C Mack

Deeba Ensan

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Sars-cov2 main protease inhibitors

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

Therapeutic compounds for HIV virus infection

Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R, L, W, W, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

The present disclosure provides pyrimidine dione compounds of Formula I

CD73 compounds

SARS-COV2 main protease inhibitors

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.

Capsid inhibitors for the treatment of HIV

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Thienopyrrole compounds

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Therapeutic compounds

The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

Cot modulators and methods of use thereof

The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

Growing community of inventors

Union City, CA, United States of America

Scott D Schroeder